Corrigendum to "Optimising outcomes for adults with Cystic Fibrosis taking CFTR modulators by individualising care: Personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework" [Respirat. Med. 239 (2025)]
Sandler, Robert D Anderson, Alan Barnett, Tracy Bourke, Stephen J Cameron, Sarah Chapman, Stephen J Choyce, Jocelyn Daniels, Thom Daniels, Tracey Dawson, Sophie
Sandler, Robert D
Anderson, Alan
Barnett, Tracy
Bourke, Stephen J
Cameron, Sarah
Chapman, Stephen J
Choyce, Jocelyn
Daniels, Thom
Daniels, Tracey
Dawson, Sophie
Affiliation
Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield; Newcastle Upon Tyne Hospitals NHS Foundation Trust; John Radcliffe Hospital; Newcastle University; University Hospitals Birmingham NHS Foundation Trust; University Hospital Southampton NHS Foundation Trust; University of Southampton; York and Scarborough Hospitals NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Blackpool Victoria Hospital; Norfolk and Norwich University Hospitals NHS Foundation Trust; University of Manchester; Derriford Hospital; Royal Devon & Exeter NHS Foundation Trust
Other Contributors
Publication date
2025-03-13
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Cystic Fibrosis (CF) is a life-limiting, inherited condition in which a novel class of oral medicine, CFTR modulators, has revolutionised symptoms and health indicators, providing an opportunity to evaluate traditional treatment regimens with the hope of reducing burden. Additionally, there is cautious optimism that life expectancy for people with CF born today could ultimately compare to that of the general population. Given this potential, there is a need and requirement to optimise treatment to balance burden with the best clinical outcomes for each person with CF in an individualised manner. Personalised data-Linkage to Understand Treatment Optimisation (PLUTO) is a clinical framework, developed within the 14-Centre UK CFHealthHub Learning Health System collaborative, designed for use at an individual level for people with CF taking CFTR modulators. The PLUTO framework encourages use of two routinely collected clinical outcome measure (FEV1 and BMI) to determine health status. Where FEV1 or BMI trends suggest that optimal health outcomes are not being achieved for a person with CF, PLUTO supports consideration of adherence to both CFTR modulators and inhaled therapy to help guide the next steps. PLUTO is designed to support people with CF and their clinical teams to individualise care and optimise outcomes for those taking CFTR modulators, using data available in routine clinical encounters.
Citation
Sandler RD, Anderson A, Barnett T, Bourke SJ, Cameron S, Chapman SJ, Choyce J, Daniels T, Daniels T, Dawson S, Doe S, Dooney M, Echevarria C, Galey P, Fitch G, Lai LY, Nightingale JA, Thomas M, Thompson R, Whitehouse J, Warnock L, Waine D, Withers N, Hoo ZH, Wildman MJ. Corrigendum to "Optimising outcomes for adults with Cystic Fibrosis taking CFTR modulators by individualising care: Personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework" [Respirat. Med. 239 (2025)]. Respir Med. 2025 May;241:108016. doi: 10.1016/j.rmed.2025.108016. Epub 2025 Mar 13. Erratum for: Respir Med. 2025 Apr;239:107995. doi: 10.1016/j.rmed.2025.107995.
Type
Corrigendum